Prospective Surveillance of Respiratory Syncytial Virus Disease in Infants and Toddlers
Completed · NCT05964582
Conditions: Respiratory Syncytial Virus Infections
At a glance
- Research payments reported, 2025
- $15,038
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 344
About the trial
- Sponsor
- Sanofi Pasteur, a Sanofi Company
- Dates
- Started 2023-07-11; completion 2024-07-02
- Results posted
- Not yet
The study is a multi-center, multi-national, prospective surveillance study in which the study participants will not receive a study vaccine but will provide a baseline blood sample and be followed for acute respiratory disease during 6 months. The 6-month follow-up will occur for the most part during the Respiratory Syncytial Virus(RSV) season (based on enrollment timing and as per feasibility). A maximum of 1000 children from 6 to \< 22 months of age are planned to be enrolled in 5 to 10 countries, 1 to 2 sites per country, targeting approximately 100 participants per country. The purpose of the study is to assess the seroprevalence and incidence of RSV disease during the study period i…
From ClinicalTrials.gov, last updated 2024-09-19. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $15,038 in research payments for this study in 2025 (11 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Ariana A. Bauer, M.D. Internal Medicine · Omaha, NE
- Shelly D. Senders, MD Pediatrics · South Euclid, OH
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Dr Shelly David Senders MD Inc $12,185
- Oakland Hills Dermatology PC $2,853
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.